Transforming the
Future of Hematology
Atavistik Bio is a clinical-stage biotechnology company focused on developing innovative therapies for patients with serious hematologic diseases. Through scientific innovation and a deep understanding of disease biology, we are advancing therapies designed to selectively target disease-causing proteins and address the underlying drivers of disease.
Our Focus
We are advancing a pipeline of innovative therapeutics for patients with underserved hematologic diseases. Our lead program, ATV-1601, is an investigational oral AKT1 selective inhibitor being developed for hereditary hemorrhagic telangiectasia (HHT), alongside additional programs targeting the underlying biology of severe hematologic diseases.
News
October 7, 2026
Atavistik Bio to Present at the Cure HHT 16th International Scientific Conference
September 24, 2026
Atavistik Bio Announces Strategic Research Collaboration with Roche to Discover and Develop Novel Allosteric Therapeutics
July 30, 2026
Atavistik Bio Partners with Cure HHT Clinical Trial Network to Advance Development of ATV-1601 for Hereditary Hemorrhagic Telangiectasia